Urinary Matrix Metalloproteinase-7 and Prediction of AKI Progression Post Cardiac Surgery
Table 4
Risk reclassification of adding uMMP-7 and other biomarkers to the clinical model for predicting AKI progressiona.
Variables
Category-free NRI (95% CI)
Category-free NRI (95% CI)
IDI (95% CI)
With events
Without events
Clinical risk factorsb
Referent
Referent
Referent
Referent
Clinical risk factors+uMMP-7
0.92 (0.60-1.20)
<0.001
0.57 (0.25-0.90)
0.001
0.35 (0.15-0.54)
0.001
0.20 (0.12-0.28)
<0.001
Clinical risk factors+uIL-18
0.88 (0.50-1.16)
<0.001
0.50 (0.16-0.84)
0.006
0.38 (0.19-0.58)
<0.001
0.18 (0.09-0.27)
<0.001
Clinical risk factors+uNGAL
0.67 (0.47-0.87)
0.01
0.43 (0.07-0.78)
0.02
0.24 (0.04-0.44)
0.02
0.08 (0.02-0.14)
0.001
Clinical risk factors+UACR
0.88 (0.50-1.16)
<0.001
0.48 (0.25-0.80)
0.007
0.40 (0.21-0.62)
<0.001
0.18 (0.09-0.27)
<0.001
aAKI progression is defined as worsening of the AKI stage (stage 1 to either stage 2 or stage 3 or from stage 2 to stage 3). bComprised of preoperative eGFR, CPB time, and change in postoperative serum creatinine from baseline at the time of AKI diagnosis. Abbreviation: NRI: net reclassification improvement; IDI: integrated discrimination improvement; CI: confidence interval.
